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ABSTRACT
The interaction of binuclear rhodium(lI) complexes Rh2(OOCCH3)4(H20)2],
[Rh2{OOCCH(OH)Ph}2(phen)2(H20)2] {OOCCH(OH)Ph}2, [Rh2(OOCCH3)2(bpy)2(H20)2](OOCCH3)2 and
[Rh2Cl2(OOCMe)2(bpy)2](3H20) with ceruloplasmin, cysteine, glutathione and coenzyme A have been
investigated using UV-Vis and CD spectroscopies. The complexes containing phen or bpy at pH 7.4 and
4.0 are readily reduced with sulfhydryl compounds, while rhodium(II) acetate is relatively stable in these
conditions. Complex [Rh2{OOCCH(OH)Ph}2(phen)2(H20)2] strongly changes structure of ceruloplasmin
leading to the decrease of x-helix content and loss of oxidase activity.
INTRODUCTION
Dimeric rhodium(II) complexes have attracted considerable interest due to their interesting
structure and reactivity [1-10], catalytic properties [1-3,5,11-13] and anticancer activity [1-
3,5,10,14-19]. The structure, reactivity, catalytic properties and cytostatic activity of
z+ [Rh2X2(OOCR)2(N-N)2] and [Rh2(OOCR)2(N-N)2(H20)2] complexes (X C1, Br, I; R H, Me,
PhCHOH; N-N 2,2’-bipyridine, 1,10-phenanthroline and their derivatives) have been investigated
[4-13]. Rhodium(II) carboxylato complexes belong to the most promising platinum metals
compounds having anticancer and biological activity [14-21]. These results have prompted
investigations into the chemical properties and biological effects of rhodium(II) complexes 14-16,
2+ 20-26]. It has been found [27-28] that [Rh2(OOCR)2(N-N)(HO)] complexes show cytostatc
activity against human oral carcinoma KB cell line in vitro. They are also cytostatic agents against
synchronously cultivated cultures of green algae chlorella vulgaris [29-30]. The compounds
[Rh2(OOCR)20-N)2(H20)2]
2+ and [Rh2C12(OOCR)2(N-N)2] are effective antibacterial agents [31-
33].
Thus the investigation of interaction of Rh(II) complexes with compounds playing crucial
role in biological processes is interesting. Glutathione (GSH) is a naturally occurring tripeptide
with the sequence ,-L-glutamyl-L-cysteinyl-glycine. GSH is generally the most abundant
intracellular nonprotein thiol. For example, in human erythrocytes, GSH is present typically at the
2 to 3 mM level. GSH is taking part, directly or in the presence of enzymes, in neutralization
processes of radicals and molecules potentially noxious for living organisms. Its role is especially
important in preventing autooxidation of cells during respiration processes. Ceruloplasmin is an
enzyme playing an important role. It belongs to the c2-globulin part of blood plasma. Its
physiological function is not entirely explained. To the relatively well recognized functions
belong: copper transport, ferro oxidase, amino oxidase and anti-oxidant activity. Human
ceruloplasmin contains six tightly bound copper ions; however it can bind two additional labile
2+ 2+ Cu ons [34-39]. Strongly bound xons are classified as three types of Cu on the basis of their
2+ 2+ spectral properties. There are three Cu of type 1, one Cu of type 2 and a dinuclear center with
type 3 Cu
2/ ions. Type coppers have characteristic electronic and EPR spectra. They show an
intense band at 610 nm (e 10000 M cm responsible for blue color of ceruloplasmin. In
comparison, the extinction coefficient of the Cu(H20)62+ complex is ca 10 M-lcm-1. They also give
EPR signal with narrow hyperfine splitting from copper (All 7 mT). The electronic and EPR
spectra of type 2 Cu
2+ are similar to those of the low molecular copper complexes (All-- 17 mT).
The two coppers of type 3 interact with one Cu
2+ ion of type 2 and form a trinuclear cluster. Two
Cu
2+ ions of type 3 are diamagnetic because of a strong antiferromagnetic interaction. They are
bridged by the oxygen atom and are responsible for a shoulder at 330 nm in the absorption spectra.
However, describing of the trinuclear center as the combination of a type 2 and a type 3 copper
center is unfortunate because the distribution of the ligands and catalytic properties differ from
those of type 2 and 3 centers. Thus, the trinuclear copper center should be recognized as a separate
type of copper cluster [34-36]. An increased level of ceruloplasmin is observed during infectious
diseases and cancer and GSH can form metal complexes with potential antitumor activity.
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Therefore it seemed interesting to investigate the interaction of [Rh2(OOCR)4] and
[Rh2(OOCR)2(N-Nh(H20)2]-+ complexes with proteins occurring in human plasma, with some
aminoacids and compounds containing sulfhydryl groups. In this paper, we describe the interaction
o f [Rh2(OOCCH3)4(H20)2] R h2(OOCCH3)2(bpy)2(H20)2](OOCCH3)2,
[RhEC1E(OOCCHa)E(bpy)2](3H20) and [RhE(OOCCH(OH)Ph)E(phen)E(HEO)E](OOCCH(OH)Ph)2
with ceruloplasmin and L-methionine, L-cysteine, L-histidine, glutathione and coenzyme A.
MATERIALS AND METHODS
[RhE(OOCCH3)4(H20)2] [40-41] (1), Na4[Rh2(CO3)4](2.SH20) [42], [RhE(OOCCH3)2(bpy)2
(H20)E](OOCCH3)2 [26] (2), [Rh2CI2(OOCCHa)E(bpy)E](3H20 [9] (3) and [RhE(OOCCH(OH)Ph)E-
(phen)E(HEO)E](OOCCH(OH)Ph)2 [29] (4) were prepared by literature methods. The purity of all the
complexes was controlled by elemental analysis and IR spectroscopy. L-methionine, L-cysteine, L-histidine,
coenzyme A and glutathi6ne were obtained from Aldrich and used without further purification.
Ceruloplasmin obtained from Plant of Serum and Vaccines (Warsaw) was purified by dialysis before
reactions. It exhibited an A610/A278 absorbance ratio of 0.039. All measurements were carried out in 0.01
M NaOOCHa/HOOCCH3 (pH 4.0) and 0.01 M NaHEPO4/NaEHPO4 (pH 7.4) buffers. The enzyme
activity of the protein was determined by a literature method involving the oxidation ofp-phenylenediamine
(PPD) [43]. Electronic spectra were recorded on a Cary 5 and a Beckman 7500 spectrometer connected with
Hi-Tech stopped flow equipment, CD spectra, on a Jasco J600 spectrometer and IR spectra, on an IFS 113v
Bruker.
RESULTS AND DISCUSSION
The interaction of rhodium complexes with L-methionine, L-cysteine, L-histidine,
coenzyme A and glutathione has been investigated using absorption electronic and CD
spectroscopy. Reactions were carried out in water at pH 4.0 and 7.4 in acetate and phosphate
buffers, respectively, at room temperature under nitrogen.
Figure 1. Absorption spectra: a) complex 1; b) l+histidine after min; c) l+histidine after 24 hours; d)
difference spectrum of (l+histidine) (histidine, 1) after min; e) difference spectrum of
(l+histidine) (histidine, 1) after 24 hours; in 0.01M phosphate buffer, pH 7.4, [1]=[3.10
.3 M]
and [histidine]=[3.10"" M]
In the electronic spectra of complexes 2, 3 and 4 in the visible region, two bands are
observed. Band I occurs at 560 570 nm, about 25 nmlower compared with that for
RhE(OOCR)4(H20)2] compounds and corresponds to the *(RhE)----)(*(Px.h2) transition. This blue
shift is caused by the _stabilization of r*(Rh2) levels in [Rh2XE(OOCR)E(N-N)] and
2+ [Rh(OOCR)E(N-N)2(H20)2] complexes due to the interaction of the orbitals of the Rh core with
n orbitals of nitrogen ligands. Thus they have a lower energy than the rt*(RhE)(5eg) orbitals in
[RhE(OOCR)4(HO)2] complexes. The intense band II at 410 420 nm was assigned to the allowed
charge-transfer transition o(RhE),-r*(N-N [4-10, 44]. This band obscures the absorption of low
intensity attributed to the rl;-(RhE)--o"(Rh-O) transition observed at 2.25-2.50 ktm " in
[RhE(OOCR)4(H20)2] complexes. The energy of the band I strongly depends on the electronic
properties of the axial ligands. Nitrogen and sulfur ligands cause a blue shift of the band I. A
considerable blue shift of band I in the electronic spectra of 1 and 4 in the presence of L-histidine
(Figure l) indicate that the amino acid molecule is coordinated along the Rh-Rh axis via the
nitrogen atom of the imidazole ring. The reaction of L-methionine with these complexes also leads
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to the formation of adducts with ligand coordinated through sulfur. This follows from the blue shift
of the band I and strong increase of absorption in the range 430- 350 nm (Figure 2).
Figure 2. Absorption spectra: a) complex 1; b) l+methionine after min; c) l+methionine after 24 hours; d)
difference spectrum of (l+methionine) (methionine, 1) after five days; in 0.01M phosphate
buffer, pH=7.4, [1]=[3 10
"3 M] and [histidine]=[3.10
.2 M]
The latter is attributable to the S ---> Rh charge transfer 1-10, 44]. This is known that L-methionine
forms a stable adduct [45] with rhodium(II) acetate [Rh2(OOCCH3)4(CH3SCHzCH2
CH(NH3)COO)2]. Compounds containing sulfhydryl group, cysteine HSCH2CH(NH2)COOH, its
methyl ester HSCH2CH(NH2)COOMe and penicillamine Me2C(SH)CH(NH2)COOH, in reaction
with [Rh2(OOCCH3)4(HO)z] (complex ligand 4) after 2 h gave monomeric paramagnetic
rhodium(II) compounds Rh(L-H)2 (L-H deprotonated acid) [45].
Figure 3. Absorption spectrum of 4 [2.5.10
-4 M], and spectra of mixtures 4 GSH at 1"1, 1:2, 1:2.5, 1:3, 1:4
and 1"10 molar ratios. Measured minute after mixing in 0.01M phosphate buffer pH 7.4 under
N2.
However, [Rh(g-OOCR)2(N-N)2(HO)]+ complexes (N-N bpy, phen) in buffer solutions react
with compounds containing sulfhydryl group giving rhodium complexes in oxidation states lower
4+ than +2. Binuclear rhodium(II) complexes with the Rhz core can be reduced to the Rh(I)-Rh(II)
.compounds containing Rhz
3+ core. There are several examples of .such ractions. The
RhzCI(OOCR)2(N-N)] complexes in CD3OD were reduced at 78 K to Rh23+ compounds using
0 2+ Co T-rays [46] and [Rh2(g-OOCR)2(N-N)2(H20)2] compounds are readily reduced with alcohols
giving mixed-valence Rh(I)-Rh(II) molecular wires [Rh2(g-OOCR)z(N-N)2]n(BF4) [47]. In the
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one-electron chemical or electrochemical reduction of [Rh2(g-OOCCH3)2(bpy)2(M.eCN)2]
2+ in
acetonitrile, the binuclear paramagnetic complex [Rhz(la-OOCCH3)2(bpy)z(MeCN)2] is formed
[48]. However, during the reduction of the [Rhz(I.t-OOCR)2(bpy)z(HzO)z](OOCR)2 complexes with
3-t- hot alcohols, compounds with a Rh core immediately undergo dlmenzatlon giving diamagnetic
complex [Rh4(g-OOCR)4(bpy)4](OOCR)z containing Rh46+ core [49]. In the electronic spectra of
the reduced complexes very intense band at 592 nm and bands of lower intensity at 440 nm, 680
nm and 780 nm were observed [49]. The formation of tetranuclear (Rh46+), hexanuclear (Rh68+), and
other polynuclear complexes has been observed during the oxidation of complexes with 1,3-
diisocyanopropane (dicp) and 2,5-dimethyl-2,5-diisocyanohexane(ddch)[Rhz(CNRNC)4]
2+
(CNRNC dicp, ddch). Intense bands were observed in the electronic spectra of the polynuelear
isocyanide complexes in the region 560- 900 nm [50-54]. The diamagnetic compound [Rh4(g-
pz)4(CNBut)8] (pz pyrazolate) has also been described [55].
Sulfhydryl compounds, GSH, CoA and cysteine, at pH 7.4 reduce the complex 4 giving
compounds which show strong, absorption bands in the region 350 750 nm. These reactions are
very fast; they were followed using stopped flow method. Compound 4 is readily reduced with
GSH giving polynuclear rhodium complexes and GSSG. When the 4:GSH ratio was 1:1, a complex
absorbing strongly at 723 nm was formed (Figure 3). This compound is EPR silent. Thus, most
probably 4 is reduced to the Rh23+ complex which immediately dimerizes giving diamagnetic
compound with Rh46+ core. In the next steps, the last compound is reduced to the polynuclear Rh(I)
complexes with an absorption at 670 350 nm (Figure 3). At 4:GSH ratios 1:2 1:10, the
compound with a band at 723 nm is not formed. This indicates that at these 4:GSH ratios reduction
is faster and only polynuclear Rh(I) complexes can be observed (Figure 3).
Figure 4. Absorption spectra of complex 4 [3.10
-4 M] mixed with cysteine [3.10
.4 M] in 0.01M phosphate
buffer pH 7.4 under N2 measured a) 0.1 second, b) 2 minutes, c) 4 minutes, d) 6 minutes and e) 15
minutes after mixing.
Reactions of cysteine and CoA with complex 4 at pH 7.4 and 4"Cys(CoA) ratio 1"1 1" 10 are
faster than those with GSH because the bands at 723 nm were not observed, at all Rh:HSR ratios
spectra were similar to those formed in the reaction with an excess of GSH (Figure 4 and 5).
Complexes 2 and 3 in reactions with GSH give similar products (Figure 6). Complex 1 is not
reduced by GSH. In the case of the reaction at pH 7.4 the band I at 589 nm is only slightly blue
shifted and a strong increase of absorption was observed at the wavelength below 500 nm caused
by S Rh CT transition (Figure 7). This indicates that the stable [Rhz(O2CCH3)4(GSH)2] adduct
is formed. At pH 4.0 the reduction proceeds easier, complex 4 is reduced with the formation of
compounds containing Rh46+ core, also at greater excess of GSH, and reduction products formed in
the reaction with cysteine are stable at least for several hours (Figure 8).
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Figure 5. Absorption spectra of complex 4 [3.10
-4 M] mixed with coenzyme A [3.10
.4 M] in 0.01M
phosphate buffer pH 7.4 under N2 measured a) 0.1 second, b) 2 minutes, c) 4 minutes, d) 6 minutes
and e) 15 minutes after mixing.
Figure 6. Absorption spectra: a) GSH [1.10
-3 M], b) complex 3 [5.10
-4 M], c) complex 2 [5.10
-4 M] and d)
GSH+3, e) GSH+2, at GSH:complex 2:1, measured in 0.01M phosphate buffer pH 7.4.
Electronic and CD spectra indicate that complex 4 strongly interact with ceruloplasmin (Figures 9
and 10). The intensity of the "blue" copper band at 610 nm strongly decreased in 5 h after addition
of complex 4 to the solution of ceruloplasmin in phosphate buffer (at pH 7.4). The CD spectra of
ceruloplasmin and of a mixture of ceruloplasmin with complex 4 (Figure 10) prove that the
addition of compound 4 diminishes considerably the content of or-helix in the protein because of a
distinct decrease of intensity of negative transitions at 214 and 221 nm as well as an appearance of
the negative transitions at 225 and 228 nm characteristic of 13-sheet conformation [56,57]. In CD
spectra in the near UV and visible region considerable changes have also been observed (Figure
10). The spectrum of complex 4 show negative transitions at 423,352 (sh), 307(sh) and 284 nm
and positive transitions at 377, 266, 252, 233 and 212 nm. All these transitions correspond to the
observed transitions in electronic spectra. However, in the spectrum of complex 4 in the presence
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of ceruloplasmin the first transition has been shifted to 440nm and second (positive) one to390 nm.
However, in this case new transitions have also been found, namely negative peaks at 352 nm and
248 nm and a positive transition at 315 nm. The negative transition at about 281 nm was observed
almost at the same energy as in complex 4.
Figure 7. Absorption spectra of complex 1 [3.10
-4M] mixed with GSH [3.10
"4 M] in 0.01M phosphate buffer
pH 7.4 measured a) 0.1 second, b) minute, c) 3 minutes, d) 15 minutes after mixing.
:Inrnl
Figure 8. Absorption spectra: a) 4 [2.10
-4 M] and mixture 4:cysteine at 1:3 molar ratio measured b) 5
minutes, c) 20 minutes, d) 2 hours, after mixing in 0.01M acetate buffer pH 4.0.
These data indicate that [Rh2(O2CR)2(N-N)2(H20)2]
2+ and [Rh2C12(O2CMe)2(bpy)2] complexes
interact with ceruloplasmin changing strongly its structure, considerably decreasing the content of
tx-helix and decreasing the intensity of the blue copper band at 610 nm. The last effect can be
explained by strong changes in the coordination geometry of the two copper atoms of type
located in domains 4 and 6 coordinated to two histidines and a cysteine, at a distance of around 2.0
A and with a methionine at a longer distance of 3.0 A and most likely change of coordination of
copperoOf type in the domain 2 where methionine was replaced by an alanine at a longer distance
of 3.7 A.
206Metal Based Drugs Vol. 7, Nr. 4, 2000
2
Figure 9. Absorption spectra of complex 4 [2.5.10
-4 M] mixed with ceruloplasmin [8.9.10
-4 M] in 0.01M
phosphate buffer pH 7.4 measured a) 0.1 second and b) 5 hours after mixing.
Figure 10. CD spectra: a) ceruloplasmin, b) ceruloplasmin in the presence of 4, c) apoceruloplasmin and d)
apoceruloplasmin in the presence of 4, measured in 0.01M phosphate buffer pH 7.4
These changes lead to the lost of oxidase activity of ceruloplasmin in the presence of rhodium
complexes [Rh2(O2CR)2(N-N)2(HzO)2]
2+ and [RhzC12(O2CMe)z(bpy)2]. The oxidation of p-
phenylenediamine (PPD) after addition of these complexes’to the solution of ceruloplasmin was
completely stopped. Ceruloplasmin contains five cysteine-cysteine S-S bridges, three cysteines
coordinated with copper and one free cysteine SH group. However, the electronic spectra indicate
that complex 4 is not coordinated with sulfhydryl groups or MeS groups of methionines because in
the electronic spectra of complex 4 in the presence of ceruloplasmin at different protein complex
4 ratios, bands characteristic of rhodium complexes containing sulfur ligands were not observed.
Thus, most likely, rhodium is coordinated with ceruloplasmin via histidine nitrogen atoms.
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